Choroidal Neovascularization Market: Spectral Domain Optical Coherence Tomography Replaced Fluorescein Angiography Over Market Growth

Choroidal Neovascularization deals with the treatment of rapidly occurring defects in the innermost layer of the choroidal neovascular membrane called Bruch’s membrane. It is associated with the generation of new blood vessels in the choroidal layer of the eye. These blood vessels grow in the area called the choroid. 

Choroidal Neovascularization Market is associated to work on many serious eye diseases, most commonly on wet macular degeneration and macular degeneration. CNV is also found in patients with histoplasmosis, eye injury ad myopic macular degeneration. The major signs and macular degeneration symptoms of these disorders are loss of vision, paracentral or central scotoma, metamorphopsia and seeming change in image size.  

Choroidal Neovascularization Market has introduced several methods for the diagnosis and macular degeneration treatment including Fluorescein Angiography (FA), Indocyanine Green (ICG) angiography , and spectral domain Optical Coherence Tomography (OCT). Out of all the diagnosis treatments, Fluorescein Angiography (FA) was the most common method practiced.  

Nowadays, Spectral Domain (OCT) has largely replaced (FA) with its new technological change into advantage and highly precise diagnosis. Angiogenesis inhibitors injection, photodynamic therapy, laser photocoagulation, low dose radiation therapy and surgery are low cost treatment. Angiogenesis inhibitors injection is the conventional method to control the growth of blood vessels by reducing the area of fluid below the retinal pigment epithelium. 

Choroidal Neovascularization Market recent experiments on macular neovascularization suggested that a potential role of angiogenic factor is the development of CNV in the coming stage. Further investigations of the gene profiles of CNV suffering patients may play important role to anticipate different therapeutic strategies. Potentially, increasing geriatric population will guide new therapy and fundamentally change the therapy and prognosis of treatment. North America is the region with highest number of affected by this disease. Asia-Pacific is expected to grow with high rate in the next 5 years and will facilitate major challenges in this market.